Meta-analysis: Interferon improves outcomes following ablation or resection of hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 7, 2010, Pages 851-858

  Singal, A K ^a   Freeman Jr , D H ^a   Anand, B S ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; BETA INTERFERON; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ABLATION THERAPY; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAMPLE SIZE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATECTOMY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 77956397191     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04414.x     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001 94 : 153 156.
2. Kim WR, Brown RS Jr., Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002 36 : 227 242.
3. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009 27 : 80 92.
4. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention. Asian Pac J Cancer Prev 2005 6 : 244 250.
5. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007 245 : 755 762.
6. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006 44 : 1543 1554.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
8. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005 25 : 181 200.
9. Maeno H, Ono T, Yamanoi A, Nagasue N. Our experiences in surgical treatment for hilar cholangiocarcinoma. Hepatogastroenterology 2007 54 : 669 673.
10. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010 8 : 192 199.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 : 1335 1374.
12. Blindenbacher A, Duong FH, Hunziker L, et al. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003 124 : 1465 1475.
13. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000 32 : 228 232.
14. Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001 20 : 301 311.
15. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002 89 : 418 422.
16. Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004 100 : 376 382.
17. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003 138 : 299 306.
18. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005 20 : 1553 1559.
19. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005 48 : 64 70.
20. Jeong SC, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007 13 : 5343 5350.
21. Kudo M, Sakaguchi Y, Chung H, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007 72 (Suppl 1 132 138.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 188.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 315 : 629 634.
24. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009 96 : 975 981.
25. Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect 2009 15 : 964 970.
26. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004 127 : S303 9.
27. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 50 : 661 662.
28. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346 : 1051 1055.
29. Kubo S, Yamamoto T, Ikebe T, et al. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn J Cancer Res 1999 90 : 1076 1080.
30. Yu S, Douglass JM, Qualls C, Arora S, Dunkelberg JC. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites. Am J Gastroenterol 2009 104 : 1686 1692.
31. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995 92 : 4562 4566.
32. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993 17 : 389 394.
33. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 : S35 50.
34. Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery 2009 147 : 676 685.